Makes matched heart stents and the balloon catheters that deploy them, all from one factory in China.
At a glance
- Depends onDownstream position: depends on 8 industries, supplies 3
- Scale
Makes matched heart stents and the balloon catheters that deploy them, all from one factory in China.
What this company is and how it runs — written from structure, not news.
Lepu Medical Technology makes the drug-eluting stents and the balloon catheters used to deliver them — both under one roof in China — which lets its engineers tune the balloon's fold pattern and the stent's strut geometry as a single matched object rather than coordinating across two separate suppliers the way Abbott or Medtronic must. Because the balloon and stent are co-optimized at the point of manufacture, hospitals in China's cardiac catheterization labs get more consistent stent deployment, and once a hospital adopts the system it tends to stay locked in through two-to-three-year procurement contracts and cardiologists trained on Lepu's specific inflation pressures. The catch is that every time the engineers improve the design — thinner balloon wall, revised polymer coating — Chinese regulators at NMPA treat it as a new device and restart an approval clock that runs two to four years, so the manufacturing line generates interface improvements faster than the regulatory calendar allows the company to actually sell them. And because both components are made in the same facility, a single disruption — a coating-line shutdown or a regulatory inspection that suspends production — breaks the matched pair at once, with no outside supplier capable of stepping in for either half.
How does this company make money?
The company earns revenue each time it sells a cardiovascular device — primarily drug-eluting stents and balloon catheters — to hospitals or distributors. Drug-eluting stents carry higher profit margins than the catheters. It also sells in vitro diagnostic test kits to clinical laboratories, which adds a separate, smaller revenue stream alongside the device business.
What makes this company hard to replace?
Cardiologists are trained on the specific inflation pressures and delivery techniques of the stents they already use — switching to a different manufacturer means retraining on new balloon handling protocols. Chinese hospital groups are also typically locked into procurement contracts that run 2-3 years with committed purchase volumes, making mid-contract switches practically difficult. Foreign competitors face an additional barrier: getting a rival stent approved for the Chinese market requires its own NMPA submission, which takes years and significant cost, so substitutes are slow to arrive even if a hospital wanted one.
What limits this company?
Every time the company improves its stent coating, its polymer formula, or its balloon dimensions, it must file a new submission with NMPA — China's medical device regulator — and wait 2-4 years for approval before it can sell the updated product. The engineering team can produce more interface improvements than the regulatory calendar will ever allow the company to actually sell, so the approval clock, not the factory, is the true ceiling on growth.
What does this company depend on?
The company cannot operate without five things: NMPA registration certificates that legally permit it to sell each specific device version in China; CE marking certification that opens European markets; biocompatible polymer suppliers who provide the materials for the drug-eluting coating; specialized catheter manufacturing equipment to run the extrusion line; and a steady supply of sirolimus or a comparable antiproliferative drug compound to coat the stents.
Who depends on this company?
Chinese tertiary hospitals that perform heart catheterization procedures rely on this company for affordable stents — if it disappeared, those hospitals would have to pay more to buy equivalent Western devices. European distributors who operate in cost-sensitive markets would lose access to competitively priced interventional cardiology products. Interventional cardiologists in emerging markets would have fewer affordable drug-eluting stent options for their patients.
How does this company scale?
Running more stents and catheters through the same automated assembly and coating lines gets cheaper per unit as volume grows — that part scales well. What does not scale is the clinical and regulatory side: every new device iteration needs its own safety and efficacy trials across multiple countries, and those trials are expensive, slow, and cannot be automated or handed off to someone else. The more product generations the company wants to bring to market, the more that bottleneck bites.
What external forces can significantly affect this company?
China's national volume-based procurement program pushes device prices down across the board — even domestic manufacturers feel that pressure, despite being nominally favored. US-China trade tensions create uncertainty around medical device export and import rules, including tariffs that could affect the company's supply chain or overseas sales. In Europe, the MDR regulation now demands stronger clinical evidence for cardiovascular devices seeking continued CE marking, raising the bar for staying in that market.
Where is this company structurally vulnerable?
If NMPA or European MDR regulators introduced a new rule requiring large randomized clinical trials specifically for domestically made cardiovascular devices, this company would be frozen at its current approved design — it does not have the budget to run that scale of trial within a single approval cycle. Meanwhile, Abbott and Medtronic, with their larger clinical-trial operations, would keep advancing their registered device generations, and the manufacturing edge this company has built would gradually be erased.
Price is read as structure — trend, levels, range, peak and volatility drawn on the chart. It does not predict where price goes next.
Sign in to view price data.
Sign in1 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow is this stock behaving?
Two structural conditions align: (1) a multi-year price band exists where the stock has, on at least two separated occasions, stopped declining and bounced upward, and (2) current price is back inside or just above that zone after a meaningful drawdown from peak. The retest is a real one — the stock is not at a new all-time high being measured as a low.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
What the company actually pays, and whether its own cash supports it.
The reported statements, read against the company's own industry.
2 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow is this stock valued?
Retained earnings are a large share of total assets; net income was positive in each of the last 5 fiscal years; shareholders' equity is in the upper part of its industry's equity-to-assets range.
Three observations co-occur: price is several standard deviations below its one-year mean, the company has reported positive net income every year for three years, and the equity ratio is in the elevated industry-benchmarked range. The configuration describes a depressed-price, profitable, equity-funded profile.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Companies that share the same coordination system — how they create, deliver, or capture value.
Companies that share active interpretations — structural patterns currently present in both stocks.
CompanyGraph